Clinical Trial Update: Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302 [Phase 3]

View source ↗

Summary

Milestone's Phase 3 safety trial of intranasal ettripamil for terminating paroxysmal supraventricular tachycardia was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Supraventricular Tachycardia

Drugs mentioned

• Etripamil (etripamil)

Snippet

Sponsor: Milestone Pharmaceuticals Inc. | Conditions: Paroxysmal Supraventricular Tachycardia | Phase 3 | Status: TERMINATED | Results posted: 2023-04-24